The drug, lecanemab, was approved by the FDA this summer. The UW study focuses on patients without symptoms who have early ...

As a practicing physician who has cared for patients with Alzheimer’s disease and other dementias for more than two decades, ...

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients as measured by one co-primary endpoint and one secondary endpoint.

Good afternoon, Chicago. It was spring 2017, and the developers of the Old Post Office project in the South Loop had serious ...

When it was first approved by the Food and Drug Administration (FDA) in January of this year, the trials showed promising results: The drug had a 27% decline in Alzheimer’s disease over 18 months.

Nov. 30, 2023 — Researchers are collaborating on a novel approach to use neuroimaging and network modeling tools -- previously developed to analyze brains of patients in the clinic -- to ...

The Self-Administered Gerocognitive Exam, known as SAGE, is a brief, pen-and-paper cognitive assessment tool designed to detect the early signs of cognitive, memory, or thinking impairments.

Excessive television-watching is tied to an increased risk for dementia, PD, and depression, whereas a limited amount of nonwork-related computer use is linked to a lower dementia risk.

As the sun sets, problems arise - especially for those affected by Alzheimer's disease. This is largely because a change in schedule can cause confusion. It's what the term 'sundowning' means.

Nov. 8 (UPI) --The Food and Drug Administration on Wednesday authorized the use of a new weight-management treatment offered by Indiana-based drug maker Lilly. FDA officials authorized Zepbound ...